FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006069417> ?p ?o ?g. }

• W3006069417 abstract "Background: NVX-208 (NanO 2 TM ) was recently examined in a completed randomized, placebo-controlled and double-blinded dose escalation Phase Ib/II safety trial in acute ischemic stroke (AIS) patients and was found to be safe in all dosage levels. Exploratory aims indicated early treatment in the highest NanO 2 TM dose cohort improved clinical outcomes of early NIHSS and 90-day mRS. In the current Phase 2b protocol, NanO 2 TM ’s enhanced oxygen delivery from the blood to tissue will be examined in early AIS subjects with large vessel occlusions (LVO). LVO patients will provide the optimal assessment for NanO 2 TM to maintain penumbra tissue viability. The Phase 2b primary objective will be to assess functional recovery and subject independence. Drug information: NanO 2 TM is an emulsion of 2% dodecafluoropentane (DDFP) in stabilizers (sucrose, PEG-Telomer-B) and phosphate buffered saline (pH 7.0) that is a highly efficient fluorocarbon oxygen transporter. Compared to previously developed fluorocarbon oxygen carriers, NanO 2 TM carries far more oxygen per gram of fluorocarbon. Because DDFP is not metabolized, almost 100% of administered doses was recovered in the subject’s breath as DDFP. Hypothesis: NanO 2 TM given early to subjects with LVO ischemic stroke will maintain penumbra tissue viability. Methods: Phase 2b study sites will include multiple stand-alone and hub and spoke systems located across the United States. Central IRB and safety monitors will provide oversight and support coverage. Key methodology includes providing early first dosage administration of NanO 2 TM or placebo (study treatment) to identify and consent LVO AIS subjects with viable penumbra. For drip and ship patients, second and third doses will be given en route or after arrival at the hub hospital and after revascularization procedures, respectively. Following the third dose, all subjects will receive study treatment dosing out to 24 hours, each dose at 90 minute intervals. 24-hour imagery assessments will confirm infarct volume. All final angiograms and 24-hour imaging data will be sent to core labs for blinded confirmatory review. Subject recovery and independence will be assessed throughout the study to 90 days. Conclusion: Study projected start date is early to mid-2020." @default.
• W3006069417 created "2020-02-24" @default.
• W3006069417 creator A5016276242 @default.
• W3006069417 creator A5033419898 @default.
• W3006069417 creator A5050625988 @default.
• W3006069417 creator A5070747321 @default.
• W3006069417 creator A5080871212 @default.
• W3006069417 creator A5086750960 @default.
• W3006069417 creator A5091246657 @default.
• W3006069417 date "2020-02-01" @default.
• W3006069417 modified "2023-09-27" @default.
• W3006069417 title "Abstract WP120: Welcoming the New Kid on the Block; The Phase IIb Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Study of NanO 2 TM Neuroprotection in Large Vessel Strokes" @default.
• W3006069417 doi "https://doi.org/10.1161/str.51.suppl_1.wp120" @default.
• W3006069417 hasPublicationYear "2020" @default.
• W3006069417 type Work @default.
• W3006069417 sameAs 3006069417 @default.
• W3006069417 citedByCount "0" @default.
• W3006069417 crossrefType "journal-article" @default.
• W3006069417 hasAuthorship W3006069417A5016276242 @default.
• W3006069417 hasAuthorship W3006069417A5033419898 @default.
• W3006069417 hasAuthorship W3006069417A5050625988 @default.
• W3006069417 hasAuthorship W3006069417A5070747321 @default.
• W3006069417 hasAuthorship W3006069417A5080871212 @default.
• W3006069417 hasAuthorship W3006069417A5086750960 @default.
• W3006069417 hasAuthorship W3006069417A5091246657 @default.
• W3006069417 hasConcept C126322002 @default.
• W3006069417 hasConcept C127413603 @default.
• W3006069417 hasConcept C141071460 @default.
• W3006069417 hasConcept C142724271 @default.
• W3006069417 hasConcept C168563851 @default.
• W3006069417 hasConcept C203092338 @default.
• W3006069417 hasConcept C204787440 @default.
• W3006069417 hasConcept C25498285 @default.
• W3006069417 hasConcept C27081682 @default.
• W3006069417 hasConcept C2780577055 @default.
• W3006069417 hasConcept C2780645631 @default.
• W3006069417 hasConcept C541997718 @default.
• W3006069417 hasConcept C71924100 @default.
• W3006069417 hasConcept C78519656 @default.
• W3006069417 hasConcept C98274493 @default.
• W3006069417 hasConceptScore W3006069417C126322002 @default.
• W3006069417 hasConceptScore W3006069417C127413603 @default.
• W3006069417 hasConceptScore W3006069417C141071460 @default.
• W3006069417 hasConceptScore W3006069417C142724271 @default.
• W3006069417 hasConceptScore W3006069417C168563851 @default.
• W3006069417 hasConceptScore W3006069417C203092338 @default.
• W3006069417 hasConceptScore W3006069417C204787440 @default.
• W3006069417 hasConceptScore W3006069417C25498285 @default.
• W3006069417 hasConceptScore W3006069417C27081682 @default.
• W3006069417 hasConceptScore W3006069417C2780577055 @default.
• W3006069417 hasConceptScore W3006069417C2780645631 @default.
• W3006069417 hasConceptScore W3006069417C541997718 @default.
• W3006069417 hasConceptScore W3006069417C71924100 @default.
• W3006069417 hasConceptScore W3006069417C78519656 @default.
• W3006069417 hasConceptScore W3006069417C98274493 @default.
• W3006069417 hasIssue "Suppl_1" @default.
• W3006069417 hasLocation W30060694171 @default.
• W3006069417 hasOpenAccess W3006069417 @default.
• W3006069417 hasPrimaryLocation W30060694171 @default.
• W3006069417 hasRelatedWork W2008303238 @default.
• W3006069417 hasRelatedWork W2053137874 @default.
• W3006069417 hasRelatedWork W2070916806 @default.
• W3006069417 hasRelatedWork W2085856001 @default.
• W3006069417 hasRelatedWork W2092761039 @default.
• W3006069417 hasRelatedWork W2314530543 @default.
• W3006069417 hasRelatedWork W2323218404 @default.
• W3006069417 hasRelatedWork W3215504950 @default.
• W3006069417 hasRelatedWork W4385375572 @default.
• W3006069417 hasRelatedWork W2243630579 @default.
• W3006069417 hasVolume "51" @default.
• W3006069417 isParatext "false" @default.
• W3006069417 isRetracted "false" @default.
• W3006069417 magId "3006069417" @default.
• W3006069417 workType "article" @default.